Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jia-Ying Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Atorvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Major Science and Technology Project of China, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
Stains and cholesterol absorption inhibitors are frequently co‐administered in the management of dyslipidemia. This study evaluated the pharmacokinetic (PK) interaction between atorvastatin and hybutimibe in healthy Chinese subjects. A randomized, open‐label, three‐treatment, six‐period crossover study was conducted involving 24 participants. Subjects received once‐daily treatments for 14 days per period (14‐day washout): atorvastatin 20 mg, hybutimibe 10 mg, or their combination. Geometric mean ratios (GMRs) and their 90% confidence intervals (CI) were calculated for the maximum plasma concentration (C max ) and the area under the plasma concentration–time curve (AUC) of atorvastatin, hybutimibe, and their metabolites, comparing combination therapy with monotherapy. At steady state, the GMRs (90% CI) for atorvastatin were 89.9 (74.6, 108.2) for C max and 103.7 (96.0, 112.0) for AUC 0‐∞ when administered with or without hybutimibe. For total hybutimibe, the corresponding values were 120.6 (102.4, 142.0) and 105.7 (97.1, 115.2), respectively. Considering the limited PK changes and good safety profiles of both drugs, the interaction between atorvastatin and hybutimibe will likely have no significant clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang Hisun Pharmaceutical Co., Ltd, Taizhou, Zhejiang, China.
Förderung
- National Major Science and Technology Project of China
- National Major Science and Technology Projects of China
Zitieren
APA
Wang, J. Y., Chen, W. J., Ruan, Z. R., Zhang, X. H., Du, J. Q., Cui, X. F., Shao, R., Yang, D. D., Lou, H. G., & Jiang, B. (2026). Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70017
Vancouver
Wang JY, Chen WJ, Ruan ZR, Zhang XH, Du JQ, Cui XF, et al. Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70017
BibTeX
@article{Wang2026,
author = {Wang, Jia-Ying and Chen, Wen-Jun and Ruan, Zou-Rong and Zhang, Xue-Hua and Du, Jia-Qiu and Cui, Xiao-Feng and Shao, Rong and Yang, Dan-Dan and Lou, Hong-Gang and Jiang, Bo},
title = {Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70017}
}
EUVIMED